Download PDF
Drug Res (Stuttg) 2017; 67(11): 640-646
DOI: 10.1055/s-0043-110603
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study

Takeyuki Hiramatsu
1   Department of Nephrology, Aichi Welfare Cooperative Agricultural Federation Konan-Kosei Hospital, Aichi, Japan
,
Akiko Ozeki
1   Department of Nephrology, Aichi Welfare Cooperative Agricultural Federation Konan-Kosei Hospital, Aichi, Japan
,
Hideaki Ishikawa
1   Department of Nephrology, Aichi Welfare Cooperative Agricultural Federation Konan-Kosei Hospital, Aichi, Japan
,
Shinji Furuta
1   Department of Nephrology, Aichi Welfare Cooperative Agricultural Federation Konan-Kosei Hospital, Aichi, Japan
› Author Affiliations
Further Information

Publication History

received 07 December 2016

accepted 27 April 2017

Publication Date:
24 July 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Aims Very few studies have ever examined the effects of long-term (>1 year) administration of liraglutide in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Therefore, we conducted a 2-year study to prospectively examine the effects of liraglutide in those patients.

Methods A total of 148 patients with T2DM were enrolled and treated with liraglutide (0.6 or 0.9 mg/day). 97 patients completed the 2-year study without protocol deviations. These patients were divided into 3 groups according to the baseline estimated glomerular filtration ratio (eGFR) (in mL/min/1.73 m2): group A, ≥60 (n=39); group B, ≥30 to <60 (n=38); and group C, <30 (n=20). The changes in blood and urine variables, and echocardiographic left ventricular mass index (LVMI) from baseline to 2 years were analyzed in each group. Primary outcomes were changes of the renal parameters of eGFR and albuminuria after the treatment of liraglutide.

Results Blood glucose and systolic blood pressure decreased significantly after 24 months of liraglutide treatment in all groups compared with baseline (p<0.05). The eGFR increased significantly in group B (p<0.05), and remained unchanged in groups A and C. Albuminuria and LVMI decreased significantly in all 3 groups compared with baseline (p<0.05).

Conclusions These findings suggest that 2 years of liraglutide treatment in Japanese patients with T2DM and impaired renal function was effective in terms of suppressing the deterioration of renal function, and reducing albuminuria. Long-term liraglutide treatment also improved glycemic control and blood pressure, and reduced left ventricular hypertrophy in this study.

Key words

liraglutide - long-term study - impaired renal function - albuminuria - left ventricular hypertrophy
 

  • References

  • 1 Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412
    CrossrefPubMedGoogle Scholar
  • 2 Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: Metabolism and clinical practice. Curr Drug Metab 2011; 12: 57-69
    CrossrefPubMedGoogle Scholar
  • 3 Avogaro A, Schernthaner G. Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol 2013; 50: 283-291
    CrossrefPubMedGoogle Scholar
  • 4 Garber AJ. Incretin-based therapies in the management of type 2 diabetes: Rationale and reality in a managed care setting. Am J Manag Care 2010; 16: S187-S194
    PubMedGoogle Scholar
  • 5 Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215
    CrossrefPubMedGoogle Scholar
  • 6 Yabe D, Kuwata H, Usui R. et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: Assessment of composite end-points. Curr Med Res Opin 2015; 31: 1267-1270
    CrossrefPubMedGoogle Scholar
  • 7 Scott LJ. Liraglutide: A review of its use in adult patients with type 2 diabetes mellitus. Drugs 2014; 74: 2161-2174
    CrossrefPubMedGoogle Scholar
  • 8 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322
    CrossrefPubMedGoogle Scholar
  • 9 Davidson JA, Brett J, Falahati A. et al. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011; 17: 345-355
    CrossrefPubMedGoogle Scholar
  • 10 Jacobsen LV, Hindsberger C, Robson R. et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009; 68: 898-905
    CrossrefPubMedGoogle Scholar
  • 11 Terawaki Y, Nomiyama T, Akehi Y. et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr 2013; 5: 10
    CrossrefPubMedGoogle Scholar
  • 12 Zavattaro M, Caputo M, Samà MT. et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: A pilot prospective study. Endocrine 2015; 50: 620-626
    CrossrefPubMedGoogle Scholar
  • 13 Hiramatsu T, Ozeki A, Asai K. et al. Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis. Ther Apher Dial 2015; 19: 598-605
    CrossrefPubMedGoogle Scholar
  • 14 Matsuo S, Imai E, Horio M. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992
    CrossrefPubMedGoogle Scholar
  • 15 Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618
    CrossrefPubMedGoogle Scholar
  • 16 Gutzwiller JP, Tschopp S, Bock A. et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055-3061
    CrossrefPubMedGoogle Scholar
  • 17 Lovshin JA, Barnie A, DeAlmeida A. et al. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015; 38: 132-139
    CrossrefPubMedGoogle Scholar
  • 18 Schlatter P, Beglinger C, Drewe J. et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007; 141: 120-128
    CrossrefPubMedGoogle Scholar
  • 19 Kim YG, Byun J, Yoon D. et al. Renal protective effect of dpp-4 inhibitors in type 2 diabetes mellitus patients: A cohort study. J Diabetes Res 2016; 2016; 1423191
    PubMedGoogle Scholar
  • 20 Rossing P, Hommel E, Smidt UM. et al. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993; 42: 715-719
    CrossrefPubMedGoogle Scholar
  • 21 Breyer JA, Bain RP, Evans JK. et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 1996; 50: 1651-1658
    CrossrefPubMedGoogle Scholar
  • 22 Yokoyama H, Tomonaga O, Hirayama M. et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997; 40: 405-411
    CrossrefPubMedGoogle Scholar
  • 23 de Zeeuw D, Remuzzi G, Parving HH. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
    CrossrefPubMedGoogle Scholar
  • 24 Hotu C, Bagg W, Collins J. et al. A community-based model of care improves blood pressure control and delays progression of proteinuria, left ventricular hypertrophy and diastolic dysfunction in Maori and Pacific patients with type 2 diabetes and chronic kidney disease: A randomized controlled trial. Nephrol Dial Transplant 2010; 25: 3260-3266
    CrossrefPubMedGoogle Scholar
  • 25 Saiki A, Nagayama D, Ohhira M. et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 2005; 29: 1115-1120
    CrossrefPubMedGoogle Scholar
  • 26 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
    CrossrefPubMedGoogle Scholar
  • 27 Rizzo M, Abate N, Chandalia M. et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab 2015; 100: 603-606
    CrossrefPubMedGoogle Scholar
  • 28 Li N, Zhao Y, Yue Y. et al. Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance. Biochem Biophys Res Commun 2016; 478: 46-52
    CrossrefPubMedGoogle Scholar
  • 29 Umemura S, Kawamori R, Matsuoka H. et al. Effects of renal dysfunction on cardiovascular events in diabetic patients with hypertension: challenge-DM Study subgroup analysis. Clin Exp Nephrol 2011; 15: 64-72
    CrossrefPubMedGoogle Scholar
  • 30 Chen F, Yang W, Weng J. et al. Albuminuria: Prevalence, associated risk factors and relationship with cardiovascular disease. J Diabetes Investig 2014; 5: 464-471
    CrossrefPubMedGoogle Scholar
  • 31 Felício JS, Pacheco JT, Ferreira SR. et al. Hyperglycemia and nocturnal systolic blood pressure are associated with left ventricular hypertrophy and diastolic dysfunction in hypertensive diabetic patients. Cardiovasc Diabetol 2006; 5: 19
    CrossrefPubMedGoogle Scholar
  • 32 Muntner P, He J, Hamm L. et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753
    PubMedGoogle Scholar
  • 33 Scheven L, Van der Velde M, Lambers Heerspink HJ. et al. Isolated microalbuminuria indicates a poor medical prognosis. Nephrol Dial Transplant 2013; 28: 1794-1801
    CrossrefPubMedGoogle Scholar
  • 34 Xanthakis V, Sung JH, Samdarshi TE. et al. Relations between subclinical disease markers and type 2 diabetes, metabolic syndrome, and incident cardiovascular disease: The Jackson Heart Study. Diabetes Care 2015; 38: 1082-1088
    CrossrefPubMedGoogle Scholar
  • 35 Ninomiya T, Perkovic V, de Galan BE. et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821
    CrossrefPubMedGoogle Scholar
  • 36 Tanaka T, Higashijima Y, Wada T. et al. The potential for renoprotection with incretin-based drugs. Kidney Int 2014; 86: 701-711
    CrossrefPubMedGoogle Scholar